Cardiogen Pen
20 mg of the Khavinson tetrapeptide AEDR in 3 mL of sterile bacteriostatic water, 0.67% w/v. Filled from a peptide lot tested in the manufacturer’s own laboratory, with a certificate.
| Compound | Cardiogen Ala-Glu-Asp-Arg (AEDR); Khavinson cardiac peptide bioregulator |
|---|---|
| CAS number | Not assigned |
| Molecular formula | C18H31N7O9 |
| Theoretical mass | 489.5 Da |
| Sequence / structure | H-AEDR-OH (4 residues; free N- and C-termini) |
| Contents | Cardiogen: 20 mg per 3 mL pen (0.67% w/v) |
| Form | Sterile aqueous solution in bacteriostatic water (0.9% benzyl alcohol), supplied in a 3 mL glass cartridge inside a preloaded autoinjector pen fitted with a needle |
| Storage, sealed | Store at 2–8 °C in the original carton, protected from light |
| Format | Solution in a 3 mL pre-filled pen |
Sizes and lots
- 20 mg · 1 pen — $88.99
- 20 mg · Kit of 10 — $791.12
Cardiogen, the Khavinson tetrapeptide Ala-Glu-Asp-Arg (AEDR) that the series assigns to heart tissue, is sold in this listing in solution: a preloaded pen with 20 mg of Cardiogen in a 3 mL glass cartridge of bacteriostatic water, 0.67% w/v. It is a peptide, not the Cardiogen-82 rubidium generator used in cardiac imaging. Published research on AEDR is limited to cell culture and computer modelling from one research network.
What is in the pen
The cartridge carries 3 mL of sterile solution with 20 mg of H-AEDR-OH, the peptide sold dry in the Cardiogen 20 mg vial. That is about 6.7 mg/mL, or roughly 41 µmol in the pen. It is dissolved in bacteriostatic water with 0.9% benzyl alcohol. The safety data sheet does not classify Cardiogen; it lists benzyl alcohol as harmful if swallowed or inhaled, a serious eye irritant and a skin sensitiser.
Keep the pen at 2 to 8 °C in its carton, shielded from light and capped once opened. Freezing is ruled out, and a solution that has frozen or looks cloudy or discoloured should be discarded. The trade-offs between ready-made solutions and freeze-dried vials are covered in peptide pen vs vial.
What the research covers
The only cell experiment on Cardiogen among these references used mouse embryonic fibroblasts. In those cultures AEDR raised expression of actin, tubulin and vimentin two- to five-fold and of lamins A and C two- to three-fold, and the authors tied this to the cardioprotective activity reported in earlier work1. Fibroblasts are not heart muscle cells, and the earlier cardiac papers are not among the references checked.
A 2023 modelling study placed AEDR among 26 ultrashort peptides whose computed binding to the transporters LAT1, LAT2 and PEPT1 beat that of di- and tripeptides with no known activity, which the authors read as a possible route into cells2. Nothing was measured in living cells.
Frequently asked questions
How does the Cardiogen pen differ from the vial?
Both contain 20 mg of Ala-Glu-Asp-Arg. In the vial it is a freeze-dried powder kept at −20 °C until dissolved; in the pen it is already a 6.7 mg/mL solution in bacteriostatic water, stored between 2 and 8 °C and never frozen.
Does any study describe Cardiogen in solution over time?
No. The AEDR papers are a fibroblast culture study and a docking model, and neither looks at how the peptide keeps in water. Follow the safety data sheet: cold, dark, capped and unfrozen.
References
- Khavinson VKh, Lin'kova NS, Polyakova VO, et al. Tetrapeptide H-Ala-Glu-Asp-Arg-OH stimulates expression of cytoskeletal and nuclear matrix proteins. Bull Exp Biol Med. 2012;153(4):559-62. DOI · PubMed
- Khavinson VK, Linkova NS, Rudskoy AI, et al. Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters. Biomolecules. 2023;13(3). DOI · PubMed
For laboratory research use only. Not for human or veterinary consumption. Products have not been evaluated by the U.S. Food and Drug Administration and are not intended to diagnose, treat, cure or prevent any disease.